CN114634932A - 一种新circRNA、试剂盒及用途 - Google Patents

一种新circRNA、试剂盒及用途 Download PDF

Info

Publication number
CN114634932A
CN114634932A CN202210242614.5A CN202210242614A CN114634932A CN 114634932 A CN114634932 A CN 114634932A CN 202210242614 A CN202210242614 A CN 202210242614A CN 114634932 A CN114634932 A CN 114634932A
Authority
CN
China
Prior art keywords
circrna
lung injury
acute lung
kit
quantitative pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210242614.5A
Other languages
English (en)
Other versions
CN114634932B (zh
Inventor
黄艳
赵大海
李洋洋
吴强
谈媛媛
孟晓明
王媛媛
金娟
徐振山
李峰
张安琪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Medical University
Original Assignee
Anhui Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Medical University filed Critical Anhui Medical University
Priority to CN202210242614.5A priority Critical patent/CN114634932B/zh
Publication of CN114634932A publication Critical patent/CN114634932A/zh
Application granted granted Critical
Publication of CN114634932B publication Critical patent/CN114634932B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/532Closed or circular
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明提供一种新circRNA,涉及疾病检测技术领域,具体涉及circRNA在制备治疗急性肺损伤制剂中的应用,是基于目前对急性肺损伤的提前诊断缺乏有效方法的问题提出的。circRNA对应的DNA序列如SEQ ID NO.1所示。本发明采用3RT‑PCR法验证对照组和模型组中circRNA相对表达量,结果显表明circRNA在缺氧缺血模型组中表达量明显高于正常对照组,差异具有统计学意义(P<0.001),是正常组的约1.8倍,在缺氧缺血的20例脑组织中70%表达趋势符合预期,RT‑PCR验证实验结果与数据分析结果基本一致,显示circRNA是很好的辅助诊断分子标志物,其与急性肺损伤具有很好的相关性,具有非常重要的研究价值和临床应用价值。

Description

一种新circRNA、试剂盒及用途
技术领域
本发明涉及疾病检测技术领域,更具体地说,涉及一种新circRNA、试剂盒及用途。
背景技术
急性肺损伤(Acute lung injury,ALI)是各种直接和间接致伤因素导致的肺泡上皮细胞及毛细血管内皮细胞损伤,造成弥漫性肺间质及肺泡水肿,导致的急性低氧性呼吸功能不全。以肺容积减少、肺顺应性降低、通气/血流比例失调为病理生理特征。其显示非特异性症状,但气短是主症状,时而伴随咳或胸痛。急性肺损伤患者典型地在从最初的伤害或疾病起24-48h以内显现出上述症状,重度的情况下会致死。死亡率为极高的30-40%,可因老龄或并存疾病而进一步提高。
急性肺损伤的诊断基本上通过临床诊断来进行。急性肺损伤的临床所见也与急性心力衰竭以及肺感染的临床所见类似,为了确定诊断或者确定原因,患者还应该进一步接受ABG检查(Arterial Blood Gas Test;动脉血气检查,测定血中的氧分压、CO2分压、pH等)以及胸部X射线检查,目前对该病的提前诊断缺乏有效方法。申请号为CN201310429807.2的专利公开miR-155在制备防治急性肺损伤药物中的用途,揭示miR-155与急性肺损伤存在密切相关性,其促进急性肺损伤的发生,证明miR-155的下调剂可用于预防、缓解或治疗急性肺损伤,特别是急性肺出血。
环状RNA(circular RNA,circRNA),一种新型的内源非编码RNA,是近期RNA领域的研究热点,circRNA是一类通过反向剪接将3’和5’末端连接起来形成的环形RNA分子。按照剪接来源的不同,circRNA可分为内含子来源环状RNA以及外显子来源环状RNA。circRNA具有如下特征:1)属于非编码RNA;2)富集在细胞浆,成环易出膜;3)具有特异的反向剪接位点;4)稳定,不易被核酸外切酶降解;5)有一定的组织特异性,时序特异性,疾病特异性;6)表达丰度高;7)物种保守性好;8)可充当竞争性内源RNA(ceRNA)的角色,进而调控靶基因的表达。
随着对circRNA研究的深入,circRNA与疾病的相关性也越来越多的受到研究者们的关注。如申请号为202010450500.0的专利公开了cricRNA在诊治胃癌中的应用,申请号为201910234595.X的专利公开了一种新circRNA及其在制备缺氧缺血性脑损伤诊断试剂中的应用。一些研究表明,circRNA在体内含量丰富,并且比线性RNA稳定,呈现组织特异性表达模式。两个独立的实验组发现内源性circRNA可以作为microRNA(miRNA)海绵来发挥作用,这意味着circRNA可以与miRNA结合,从而阻断miRNA对其靶标表达的抑制作用。这表明circRNA在疾病的发生和发展中发挥着重要的作用,有望成为例如癌症、心脏病、神经系统疾病、动脉硬化等疾病的生物标志物。
发明内容
本发明所要解决的技术问题在于解决目前对急性肺损伤的提前诊断缺乏有效方法的问题。
本发明通过以下技术手段实现解决上述技术问题的:
一种新circRNA,序列与SEQ ID NO.1具有90%以上序列同源性。
术语“同源”是主要是指序列上的同源,也就是用来说明两个或多个RNA或DNA序列具有相同的祖先。同源的序列一般有相似的功能。一般来说,当相似程度高于50%时,常推测检测序列和目标序列可能是同源序列;当相似性程度低于20%时,就难以确定其是否具有同源性。
优选地,序列与SEQ ID NO.1具有95%、96%、97%、98%或99%以上序列同源性。
优选地,所述circRNA对应的DNA序列如SEQ ID NO.1所示。
本发明还提供一种检测急性肺损伤的荧光定量PCR试剂盒,所述试剂盒检测样品中circRNA的表达水平,circRNA序列与SEQ ID NO.1具有90%以上序列同源性。
优选地,所述试剂盒采用测序技术、核酸杂交技术或核酸扩增技术检测样品中circRNA的表达水平。
优选地,所述试剂盒采用二代测序技术、三代测序技术、探针杂交技术、基因芯片技术或荧光定量PCR技术检测样品中circRNA的表达水平。
优选地,所述试剂盒含有与circRNA杂交的探针或扩增circRNA的特异性引物,特异性引物包括上游引物和下游引物;还包括内参引物、荧光定量PCR反应液,内参引物为GAPDH内参引物。
优选地,所述试剂盒采用特异的引物检测样品中circRNA的表达水平。
优选地,所述上游引物序列为SEQ ID NO.2,下游引物序列为SEQ ID NO.3所示。
优选地,所述样品包括肺组织或外周血。
本发明的目的还在于提供上述circRNA在制备治疗急性肺损伤制剂中的应用。
进一步地,circRNA调控的miRNA选自下列miRNA中的一种或几种:rno-miR-132-3p、rno-miR-219a-2-3p、rno-miR-466b-4-3p、rno-miR-466b-3p、rno-miR-466b-5p、rno-miR-146b-5p、rno-miR-466c-3p、rno-miR-6216、rno-miR-206-3p、rno-miR-3473、rno-miR-466b-2-3p、rno-miR-293-5p、17_41438、17_41409、17_41456、17_41426、17_41422、rno-miR-212-5p、rno-miR-127-5p。
本发明的目的还在于提供上述试剂盒在制备急性肺损伤诊断制剂中的应用。
定义:
环状RNA(circular RNA,circRNA),亦称环形RNA,是最近几年研究确认的一种新型的非编码RNA(noncoding RNA,ncRNA)分子。根据RNA构成的不同,环状RNA可分为三类:外显子环状RNA(exon circular RNA,ecircRNA)、内含子环状RNA(circular intronic RNAs,ciRNAs)和外显子-内含子circRNA(exon-intron circRNA,EIciRNA)。
“探针”指能与另一分子的特定序列或亚序列或其它部分结合的分子。除非另有指出,术语“探针”通常指能通过互补碱基配对与另一多核苷酸结合的多核苷酸探针。
所述探针具有与靶点基因的特定的碱基序列互补的碱基序列。这里,所谓“互补”,只要是杂交即可,可以不是完全互补。这些多核苷酸通常相对于该特定的碱基序列具有80%以上、优选90%以上、更优选95%以上、特别优选100%的同源性。这些探针可以是DNA,也可以是RNA,另外,可以为在其一部分或全部中核苷酸通过PNA(Polyamide nucleicacid,肽核酸)、LNA(注册商标,locked nucleic acid,Bridged Nucleic Acid,交联化核酸)、ENA(注册商标,2′-O,4′-C-Ethylene-bridged nucleic acids)、GNA(Glycerolnucleic acid,甘油核酸)、TNA(Threose nucleic acid,苏糖核酸)等人工核酸置换得到的多核苷酸。
本发明中的术语“杂交”用于指代互补核酸的配对。杂交和杂交强度受诸如以下的因素影响:核酸之间的互补程度、所涉及的条件的严格性、形成的杂交体的Tm和核酸内的G:C比率。
测序技术主要为高通量测序技术(High-throughput sequencing),又称下一代测序技术(next generation sequencing),一次对几十万到几百万条DNA分子进行序列测定,极大提高了测序效率。高通量测序平台的代表是罗氏公司(Roche)的454测序仪(RochGSFLX sequencer),Illumina公司的Solexa基因组分析仪(Illumina Genome Analyzer)和ABI的SOLiD测序仪(ABI SOLiD sequencer)。
Northern杂交,又称RNA印迹技术为最经典的检测真核生物RNA大小,估计其丰度的实验方法。基本原理如下:首先在载体(如硅片、微球或膜等)上固定RNA样本,再与经过标记的探针杂交,洗涤多余的杂交探针后进行信号检测;也可以在载体上先固定与靶RNA序列互补的DNA探针,然后与经过标记的样本RNA杂交,再进行信号检测。信号标记的方法包括同位素标记、荧光标记和纳米金标记等。
附图说明
图1为本发明实施例提供的circRNA及其调控的miRNA网络图并包含部分miRNA的靶基因;
图2为本发明实施例提供的验证正常对照组、急性肺损伤组和ASIC1a抑制组的circRNA的差异表达图;
图3为本发明实施例提供的验证正常对照组、急性肺损伤组和ASIC1a抑制组的miRNA差异表达图;
图4为本发明实施例提供的验证急性肺损伤患者肺泡灌洗液中的miRNA的差异表达图。
本发明的有益效果在于:本发明采用3RT-PCR法验证对照组和模型组中circRNA相对表达量,结果显表明circRNA在缺氧缺血模型组中表达量明显高于正常对照组,差异具有统计学意义(P<0.001),是正常组的约1.8倍,在缺氧缺血的20例脑组织中70%表达趋势符合预期,RT-PCR验证实验结果与数据分析结果基本一致,显示circRNA是很好的辅助诊断分子标志物,其与急性肺损伤具有很好的相关性,具有非常重要的研究价值和临床应用价值。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合说明书附图和本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
下述实施例中所用的试验材料和试剂等,如无特殊说明,均可从商业途径获得。
实施例中未注明具体技术或条件者,均可以按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。
实施例1
急性肺损伤大鼠模型的建立和取样:7日龄新生SD大鼠,体质量10-14g;随机分成两组,假手术组(正常对照组)和急性肺损伤组,每组8只;假手术组不再做任何处理;急性肺损伤组气管滴注LPS(5mg/kg);ASIC1a组是在急性肺损伤组基础上,提前24h尾静脉注射PcTx-1(25μg/kg)。将各组大鼠用4%水合氯醛麻醉下,打开胸腔,取肺组织立即放入液氮冷冻保存。
实施例2
高通量测序及数据分析:
2.1组织总RNA提取及质检
(1)取适量组织(50-100mg)于匀浆器壶部,加入1ml Trizol裂解液,并用剪刀剪碎组织,然后在冰上用匀浆器匀浆至肉红色,冰上裂解10min;
(2)将组织悬液转移至1.5mlEP管中,颠倒混匀10下,室温静置5min;
(3)加入细胞悬液五分之一体积的预冷的氯仿,剧烈震荡1min后于冰上静置10min,于4℃下以12000rpm的转速离心30min;
(4)转移上层水相到新EP管中新的去RNA酶的EP管中(注意避免触及中间层),加入等体积预冷的异丙醇,颠倒混匀,-20℃助沉1h,于4℃下以12000rpm的转速离心30min;
(5)弃上清,加入预冷的无水乙醇1ml,涡旋振荡,洗涤RNA沉淀;
(6)于4℃下以7500rpm的转速离心10min,弃上清,打开超净台风机干燥5min,晾干后,加入适量DEPC水充分吹打溶解沉淀。
RNA质量检测标准,使用Thermo Nanodrop 2000分光光度计测量RNA浓度和OD260/OD280的值,OD260/OD280值小于1.8提示存在蛋白等污染,介于1.8与2.1之间,蛋白纯度较好,大于2.1,提示RNA降解过多,最终结果表明RNA纯度较高,无蛋白质或DNA等污染。
2.2circRNA测序检测
(1)全转录组测序建链特异性文库流程,包括Ribo-Zero Deplete and FragmentRNA、Synthesize First Strand cDNA、Synthesize Second Strand cDNA、纯化、Adenylate3'Ends、Ligate Adapters、纯化、Enrich DNA Fragments、纯化、文库质检;
(2)原始测序数据及质量控制
原始测序数据及评估,高通量测序得到的原始图像数据文件经碱基识别(BaseCalling)分析转化为原始测序序列,被称为Raw Data或Raw Reads,结果以FASTQ文件格式存储,其中包含测序序列(reads)的序列信息以及其对应的测序质量信息。测序得到大量的样本数据。鉴于数据错误率对结果的影响,对原始数据进行质量预处理,并对整个质控过程中的reads数进行统计汇总。
测序序列质量评估,包括碱基质量分布和GC含量分布。
circRNA测序序列评估,包括测序饱和度分析、测序随机性评估、Reads在不同元件的富集分析、基因覆盖度分析、Reads在参考基因组上的分布。
(3)circRNA鉴定、注释、定量
测序序列使用CIRI软件进行circRNA预测,将预测结果与现有circRNA数据库比对,得到己知cricRNA和预测的cricRNA;在circRNA预测方面,主要基于数据库中释放的蛋白编码基因及转录本的注释信息,通过位置信息比对,获取与circRNA在位置上有着最大重叠的转录本,基于该转录本信息,对circRNA的序列进行预测。
CircRNA的注释主要是与已知数据比较、circRNA来源基因注释、circRNA基因结构分析。
circRNA的定量:用RPM对circRNA进行定量,对各样本circRNA表达量及丰度(RPM)进行统计。
2.3差异表达circRNA分析
利用CircSeq数据比较分析两个样品中同一个circRNA是否存在差异表达的时候,可以选取两个标准:其一,foldChange,即两组样品中同一个circRNA表达水平的变化倍数;其二,pvalue或FDR,FDR值的计算方法先要对每个circRNA进行pvalue的计算,再用FDR错误控制法对pvalue作多重假设检验校正。其中,定位于染色体18(染色体上的位置:65825830|65841509)的一circRNA上调差异表达明显,具体序列如下:
SEQ ID NO.1:
CCAAGTGGTAAGAAGTTCAGAAGTAAACCGCAGCTGGCGAGATACCTGGGAAATGCTGTTGACCTTAGCAGTTTTGACTTCAGAACCGGCAAGATGATGCCTAGTAAATTACAGAAGAACAAACAGAGGCTGCGGAACGATCCCCTCAATCAGAACAAGGTTGGTAAATGTACTTGTAATGTGGACATGCACTTCCTAGGCTCTCCACCAGTGTTTCATGTTGTGTTTGGGTTGTGATCTTGGTTGGCTGAAAATGTCTCTCCCTACTACAGAGCCTTTTAAAACTTACAAGTGAGACTTATGTTTCTATATTTGGAAGTGCTTGGAAAAATGTGTTAAGTAATTGTGCATAGTAGAAAACAATATTTCAGTATGTCATTAGGCCAACATGGGCACCAACCACACTTTGTGACTTTCTCTTTTTTCTTTCATTCATTCATTCATTCATTCATTCATTCATTCATTCATTCATTTTTCAAGATACGGTTTCTCTGTGTAGCCCTTGTTATCCTGAAACTCATTCTGTAGACCAAGCTAGCCTGTAACTCAAAGATATCCCTGCTTTTTCCTCCCAAGTGCTTGTATTAAAGGCGTTCATCATCACCATTTATCTGGCTTGTTTTTTTCTTAATTTTTTTTTCTATTTCCTAAAAAGAGGCAACATTCCCACATAGTGTATTGTGTCTAATTTTATAGTTAGTTCAGAAGTTGTGCCTTTGACGGTGATGACACCTACCCGTAGACATCACTGTTCTCGTCAGGTTTCACGAGCTCTAAATTTTCTTGAACTTGTTGCTTGACTATTCTGTAGCAATATAAATAAGTTACATTTGAATATGTTAATTTAATTTGAGGCTTTAGAATCTTTTTTTTTTTTTAAAAGCTTCTGTTCTTCCAAGGACAACTGGCCATGTATGACCCACAGATGACGCATTGCCTTGCATGGTTCCTCTAAGTATGTTCTCACCTCAGCACTGAGACAGGAGCTGAGGTGAAGTCACTGCAGGTTCCTCAGGGATTTCAGGGACTTTGTTATCAGTTGTGAAAGGGCTTCATTTCTGTACATTTAGGAGTCTGTCTGTGTGTTACCATCAACACACTTTCTCCCTCAGGCTTGTGAAGTTCAGGGTGAAAAGCAGAGGCATTTCTTAGGCTCTGACTGCTGTGGCCGGCCAGAGCCTCAGTGTGCAGTCCTGAGGAAGCAGGCTGTGGGCTCAGGCGGGCGGGCTATGCTGGGTTTCAGCAGCTACACTCACTCACACACAACATTCTTACTCTGAAGGCCCGAGGCCTTTTGTAGAATTGGGCAAGAAAACTCCTATAGCTTTATCATGAGAAAATACAGTGGGAATTTACATAAAAACATTTAACAAAGTATTGACCCATGCTATTTTCCTTTTTTTCAAACTGCCCTTTCCTTCCTTAAGGGGCAGCCACCTTCTGAGCACCGAGCCATCCTGCTTAACATGGCGTCCGGTGTAGGAAGCTTTCTGGTTCAAGCTCTTTATCTCATTTTTTTGTTTTTGTTTGTTTTTGTTTGGAATACACAAACTCACACACACATCATGTGCGTGTGTGTAATATATTGATGGATATAGCGACTACATTTTTCTAGAACTGCTGCTGTAAACTCTAGTTATAGCACTGCCTGCATGCCTTAGAAGGACTTACATATTTATGAAATGAAGAGAATGTGTTTAGATTACCCTGCTGTGCCCAGAATCACAGTTTAGCCTCCTTTAATGTAATTTGAAGCTTTACGTCCTGACAGTTATGGTTCGTTAAACCCCAACACTAATTGGTCTCTAGTTTGTGTGCACCCTTCTGCTCTAGCCGCTCTGGACCGCTCTTCACCCCGCAGCATGGCATGCGCTTTCGGGATCTGCTTGCTTCTGTGCTGTTTCCTCTGCTTGGAATGTGCTCCCCTCCCCCTCACCCGGTGACCTCCTCAGCTGAGGCTCAGCTCCATTGCCTGCATACCGGGGAATCCTGTCCCTCCCTCCGAGATGACCATGTGCTTCAGCTAGACTGTGAGCTCCACGAGAGCAGGACTCTTTGCTTTGTTGTTTTGTGTAGTTGCCCCAAACCTTGCACGTAGTAGCCTATTAAATAAATACTGCTTTACTCTCCATTTGATTCTAGAAGGGTGTAGTGATAATAAATGCTTATTCAATAAATGTGTACAACACGCGTGTGGAGGTGCCGGTTGTTTTCATTGTTTTCCACTGTGTGAAGGTTGTGCTGCCTGGTCTACCTTGACCTGAGTTTTGTTTTAGGGAAGTAGCCACAGTTTTACAAGCAGACTTGCTTTGGGAGTGACACTATCATTCCAAGCAGGAAAATGTGGTAAAATGAAGTTGTTTTTCATGACGCGCTGAGTAAAGAAAACTGGGAATGACAAGTGGCAGACAGAAATCTCAGTATGCAGCAAGCTTGGTCAGGGGTAATTACTCATTGGGTACTTTCCTTTTTTTAAGTTTTTACAAGAGGTTTTCTTCTTAGAACTGGGGATATAGTCAACAAGGAAGGAAGGTTTTAAACAGGATTAACCGACTGTAAGTTGATCTTAACGTCTGTCTTCTGTATTATTGCTAATGAATGGTTATTTTCAAGTATCATTAGAAGGACCCCTCTGAAGATCTTCACCAGCGCCCTTCAGTCATCCTCCGGTGGGCGGGAAGGGAGCTGGGCATTGCCCTTGGATTAACACACTGCAGGTTTTGTACCTGTTTTGCTTTTCTCAAATTTAGTCTTAATCTAGCCCTCAAAGTTGATTGCATTCTTGATTTGATTACACTTTATTGATTTTTCTTGCTACTGCTATAATTATTTGCAGACAACCTATCTCTCAAGCTGATAAAATCCATCTGAGATACCAAGTTACTGAGGCTCTCACTAGGGTTAATGGGAGCGGCTGACTCAGAATAATAGGAAGTGGCCAACTTGAGTGTGGTGAAGTCATAGCAGTTTGACCCCAGTGGAGCATTCTGGGATGGAATTGTGGTAGCTTTAGCCACACATGTGACCAATACGCAGTTACATATGCGTGGACTCCTTGGATTTCTAGAATGAGAAGGCAAAGCTTCAAATACTCACACAGACACACACACACACACACACACACACACACACACGCACACACACATTTAGACTTTTAAGACATATTTCAAATTTCAGAGATAGGATTTGACATTTTAAGGAGGCAGTGGAGACAAGATGGTAATTTCGGGTGACTGAGATGGCTGAGCAGTTGAAGGCCCTTGCTGCCAAATCTGATGACATGAGTTTCATTCCCATGACCCATGTAAAGATGGAGAGAGAGAGAGATCACACACACGCACACACATATACACATGTACGTACACATGCATGCACACACATGCACACACATGTACACAGATGCACACACATACACATGTATACACACATACACATGTACACACACATACACATGTACACACATGCATGCATACAGAGTGGGGGAGGGAGACTGGGAGGAGAGAGAAAATATAAACAATATAAAACTAAGATAATGTCTAAAGCTGACGTGGAGATATTCTAGGATGAGCCGCATTAGGTTGTTTGTACAAAGCAGGCTTAGGGAACTTTGGAAACTTGGTTCTGTTAGAAATTCTACATTAAGCTGAATTCCTTATGTTTCTGTCTTTTAATACTACAGTATTAATGGAATATCATAACGAAGCTGCAGAACTTAAATGCACATGTCCTGACCTTGATGTGGTCTGCGATAGATTTTGCAGGTTGCTTACAATAGACATGTGGACCCAGTCTTCCTGAGTGAACTTGAGAGCACTGCTGTAGCCTTAGAAGGTGCCACTCTGTGCCTGGCCTGTTCCTCTGGGTGAGGTCAGGTCTGTGTCAGATCTGCCACTCTTCATTTCTCATGGGCCATCTCCTGTAGTGTGCATAGTCAGTATGTCATTGTGCATACAGGCACAGACTTAGATTATGTATGACCGACTGTATCCTAGATTTTTAGACACACGGAGAGGATACATGTTTCAATTATCCTCATGAAATAATAAAAATTGCACTTAAGCTCAGTAGTGTAATTTGGAGGCAGTTACTGTGTAGCTAGTGGATAGCTAGCCTTTGGGTTAGGCAGCATGCACTGTGGAGAAGCATGCAGCGTGCAGCATTGCAAGCGGGCGAAGCTGGAAAGGCACAGTGCTAGCTGGGCTCTTTGAGTCCAGAAAGCAGCAGCCCTGAATTAGTGCTGTGGCAGGAGGCCTGGGAAGGGGGAATCGAGAAGTGAGTAGATTTAAGTGCCTGCTGGTTACAGCGAAAGGGAATTGATGCTTCCTAAAATTGTGGCTTTGGTCACTGCTGCAGTTTGGGTATACTTTGTCTCCTAAAAGTTCTTGTCTGGAGACGTGGCCCTCAGTACTGTGATTTTGAAGCGGATGGGGTGGCCCAGTGGAAAGTGACCAAGTCATAGGGTTCCATTTTTATAATGGATTAACGCCACCCTTGGAGGGAGCATTGTGGCTTTCACAGGCATTCCTCTAACGGAGAGCTGTAATAAAAAGATCAAGCCCAGCCTTTTCCTTCTCTCGCTTCTCTGTTTGCATACCTGTCCCCTTGCTGGCACCATGCTGTCTAGCCAAATAAAGCCCTAAGTTGCCTGAGCCCTAGGTATTTTGCTTAGCAACAGCCAGTTGAGTCTTTCAAGAAATAGAATGGCTGCTGCTGAAGGGTTGACCAAAGAAGACAAAACTTTATTGAGTTTGACATTTTAATTACCCTTCTTTTGAGACAGGGTGTTTCTACATAACTTTCACTGTCCTGGAACTCATTATGCAGACCCAGGCCAGCCTTGAACACAGATCCATTTGCCTCTGATTACTGGGAACTGAGATTAAAGGTAGCAAATATCAGCATAGGAAGCTTTAATTAGCTCTGAGCACTAGGTTTTGTGGGGACAGAAGCCAGGTTGGATTGTAATGTGAAATTGGACAGCAAGGACAGCTATTCAGTAAATTTTCATAGGTAAGTTTGAGAGTCACTGAATAAGAGAGGAAAGAGACGACACTTCAGTTCAAAGATTGGAATGGTTAAAAACATGGGTCGTGAGAGAAGGAATTGTGGAGATCAGAAAACTGTGTTCTCAGATAGCAAGGCCATGTAACTACACTAGTTAGGGAGGAATGTGAAAGGCACAGGAAACTAAGGAAAAGGGATAGTCAACTGATGGAGATTTGGGGGTCCGAAGGAGGGAATGGCAGCCCTGAGTTGTGAGCTGCAGACCGGAGGCTTCATTGAGATCTGGAAATAAGAGTTGCTGCTTTTGACCCAGTGTAACTAATGGCAGGTAAGTGAGGTTGAACAGGGGAATGGTCCAAGGACAGATGGAGGTCTCCAAAAATGAGGACAGAGTTTGGGTTTAGAAGGACAAAACATAATGAACTAAAGGATGGTGTGTGTGTGGGGGTGTGTGTGTGGAGGAGTCAGAGACTGGGGGCTATAAAGAAGCTGCTGCTTTGGAGGGAGAAACAATGGAGAAAGTCTAGAAAGCAGTAGGGAGAGCAGAAACAACCTTTCGGATCCCTAGATGCATTGTCTCAAGGGGTCAGAGAAAGGGGCCTGAGTCTAATGACTGGGACTGCATATAGAGAACTGAGCTTTCTTCTCGCTCCCAGTTAGCTGCCCTAACACAAGCTCACTCCCCCACTAATAAACATAATTTAAAAATTAAAAGAGCTCTGGATGTAGCTCAGGGATAGTGTGAACTTAGGGATTGTTTCTTTTATATTAATAAATTGGAGCAGACAATCTTCCTTTTCATGACAATAATTTTAATGCAGATCATACAGATTAAATTTAATTACATTATTTTTCGTTTAGTACTTTTAAGTTCAAGACAGAAATAAGATTATTCAGGCTAGGGCTGTTCGATGTAGGGCTAAATGTGTAATGGCATTTTGGCTCTAATTAGCTTATTGGAAAGAATTTTCAAAGTTGAGGCAAGCATGATTCTAAATTTGAGACTTCTGTAGAGGAAGTCCCAGGAGATTCTACTTGAGGGGGATATAATTGATCAATTAAAATAGTGCGGTGCAATGTGCTAAGTAATACAAAGGTGACTGGGTGATATTTTAGGTAGAATGTTGATGACAAGTTTCTCCGCTAGTAAGGTTTAGATGAGTTTTGAATGGCAAGTGACCATTCTCCAATAACTTGAGAGAAAAGCTTTCTATGCGAAGGAAAGAACTTGTGCAAAGTCTTTAAGGAAAGGTGCACCAGTATGTGAGTGAGGACAGAAAGAAGGGGAGGTGTTGGAGTGAACTGAGTGGAGAGCGGAACCCAGATGAGGTTGAAGACGACGACGACGACGAGCTGCCCATAGTACAGGGTAATACAGAAAGGCCCAGGCTCGGTGCAGTTACACGTTAAGAATGTATTGTAGGGTAGCAGAAACAGGCCAGGGTTTGAGTTGGGATCTGTTGAGGACTACTGTACTTGTCCAGGCAGGTGACAATGACTTAGGCAGTGCATATTTTATGAATTAAAAAAAAATAGAAAAGAAGACTGGTCAACTGGTCACTATTTTTTTCCCCAAAGAGTTTATAGTTTTATGTGTACAGAAATATCCTTAATAAATGGGTAAAGGCTATTTTCCCTAATGAATAAAGTCATTATTAATTAGACGCCATCATTGCTGCTAATTAGCCATTTATTTAGAAATTTGGGTATAATAATAATAGTAATAGTAACACAAGTTATAAGCTTGCTGGTGAGAGCACTTTGGTCAGTAAAGTGTTAGGTTTGTCCAGCTTTTGGGGATTCACATGTATCCCACTGTGGTAGAAACCTCTGAGAGCACCTGGACTTGGATGTCACATTAATAATGGAGGTCGATTTGAGGATATGGTTGTGTGTGTCATGACATTCATGTGGTTTTATTTGGCTACTCATTTCTGCTAATGATTTCATTAAATTTTATAGCCCAATTTTCCAGACCTAGAATCTGGGGCCATTGTGTCATACAAAAAACCGCTTGTGTGACTTTTCATAGTTCTCCCAAGAATGCATACACATGTCAAACAATTTTCTATTCCCTGGATCTAGAGATACAGGGGCTGTAAACTGACATGGTTCCAGGAAATGAACTTGCATCCTGCAAGAGCAGCAAGTGCTCTTAATTGCTGAGCCATCTCTACATCCGTGTGTGTGTGTGTGTGTGTGTGTGTGTTCGAGAGTGTGTGCGAGCGCCTGTGCCTCCCTGCCTGCCTACAGCATTTATGTGCACCACATATATGCAAGAGCCCACAAAGGTCAGAAGAGAGTGTTGGATCCCCCGGAACTGGAGTTAAAAGTGTGAGTCACCATTTGGATGCTAGGAACTGAACCTGGGTTCTGCAGAAATAACACGCACAGAAGCCATCTTTACAGATGTACTTTTAAAAAGCTATGATGAATTGCCAGGCAGCTTGCATTGTGGGCGTTTGATTTTTGTGAAATTTGAAATTGCTACTTGAAAATAACCTTGCTTCTACTCAAGCACATGCAAGTTATAACTGCCCTGGAAAACCATAAAAGGTTACGTGTCTTAAGTTTCTGTAGCATGCCTAGTAGTGTGTTAAAGGCCGGTATTTATTCAGGATTGATTTGCCAAGACAATCACACACTTTTTTACTGATGATCTTCATCTCTCTGCCTTCTGGAATGTAAGCTCTAAGGCAGGGACTGTTTACAAATGACATTTTCAGCTTCGGGTTAGGACCCAGCACACAGTAGACACAGTCTTTGCACAATGACTGGCTAAGACTGTATCAGTGTCATTATCATGGCCATTTTGTTTGATCTGTAGAAGAGTTGCAGTAATCATCCTGACCAACGGATAAGGGAATTGACCATAGTGGCAGCGAGTCTTTGCTTCCCCATTAGGGTATAAATATCTCTGGAACATGTTGTGTACTCAAAGCTACAGAACGAACATGGTACATGGTGATATTTTACAGTGTCAGTTCTAAAGGAGCACTTAGGGTAAGCAGAGCCACAATTTTCACCCTGCGATAAAATAAAATTTCAAAGTGAAAAGTTATTGTCAGTGTGAAAGTAAACCTTCTATGCTGTGGTTATAGGGTTAAGCTATCTTTCATCCAGCTTTTCTCCAAACCTGACTGACAGGGCTGGAGATGGCTCCAGGGTTAAGAGGACCTCCTGCTCTTACACAGGACCAGGGTTCAGTTCTAGCACCTGCAAGGTGGCTCACAGCTACTTTATAAGTGCAGTTCCTGATACTCTCTATGCCTCTGCAGGCAATATGACCAAGTGATACGCACAGAAACACGCAGGCAAACACATTCATACACATAAAATAAAGATAAATTTTAAAAGTCTGTCTAAAGAAGGTGATACATAGAGTCTAAGTCACTATGCTGTAACAGGTAAATTTCTCATGCATATCTATCTGTAAGACTTCTTGTGGGGTTGGAGTCAAACCCAGGGCTTTGCATGCTATGCAGGCACTTTCCCACTGAGCCATGCCCATGCTTTACACACGTGACCTGGAGGGAACTGAGGTCAGCATATCTTTGAAGCTTCATAAACTGCATGGTTTCCTTCAGTCTCTGAGGACACCTGTATGGATATTTTTTCCTCCACATTTTCCCCCTAGCAACAACCTTTCATATTATAGATGTGCATGCTTCTCACATGTGTGTAGTGTCAGAATGGCAGTCAGTGCTGTGCTGTCGATAGAGGAACAGCTGGAAATACTGGATTGAAATGAATCACTTGGTAACAACTTTTCCCACAAATAAAACTCTGAACAAAATGTAGGGAACTTTATGTATCTGTCTACTGATTATTAAGGGTTTTTTTTTTTTGATGTCTTACAATCAAATTGTCTTAAAATGTGATATTTTAATACAAACTCTTAAAAGCAGTTCAAGGTCTGAGTCACAGGGTGAATGCATTCTTCCCAGTCATGTGACCAGGACTTTTCAGTGCCACCTCATCTAGAATAAACGGAAATAGGAATAGAATTGATGTTAGCAATTAGTAACACTTATCAAAGAACATGAAGGTATTTAAAAATTCTTGCAGTCAGGCATACTTGAGTGTGCCCATAATCCAGGGACTGGGGAGGGCAAGGCAGGAGAAGGATCATTTGAGACCAGGGGTTGGGAGGCCAGCCTAGGCAATGTAGCAAGAACCTATTTCAAAAACAAGAAGTAGAAAAGGCCCCACCAGCTTTCCCTTGGAGCTGTAGCTCATTTCTGAAGTTAGGTATGTTTAGTAGTTACTTTAAAATTGTAATACACCATGTTTGGTAAAACAGTATTTTGTTTTAAACATGAGAGCTTTATATGATCACAGGAAATAGAAAGATACCACTAAATTTCAGTTGGATAAAATACTAATTAATATTAATAGTACTGATAAAATATCACTAAAGATTTTTTTCAAGTCTGAAATTGGAAATAACTTTGGAAATGACATTTTTTATTCAAAAACAAAATGTAGACTGCTGACATGTTCCCTCGTGTGTAGAGGATCGATGGCTTTTTAGTGTGTTATTGTGTAACTAGGCAGAACTAAGACAGTTCCACTTGTAATTACCTACCTTAAGTAAAATGGAAACTGATGGCAGCTTTAGAGGGCGGTGAGCTGCATGTACTTTGAACATTCTGAGGAGGCAGGGTAGAAATGCCGGCGGGTGCTGGTTTATAGAACAGTTCTACAACCTGTGTCTCGGTGACCCGTTCCACAGTACTGAGACCCATCCCTTCCCAGCCACTTTCACTGCGTGGACCTTAAGTCTTAAGTCACAGGTATCTGTGGAAGGCCACTGAAGAAAGTAAAAACAAATCTGCTTCTTTAACAGGACATATTTTTAGAGTTTTAAAGTTCACGAGCTTTTGACTAGAGGGCTGGGCTGGTTTATAACATTGCAGTGAGTTTGCTGGTTAAGTTTGTAATGTAAAGGAACTTCACTTTTTTTATATTTAAAGAGGATTTCAGTTTTATGAGCAGCTGTAATTGTGCTTCACGCCCAGGTGATGGTGTTTAATGCCCAGGCTCATGGCAGAGTGCCAGTGGTCTAGGCAAACTCAGGTAGCAGGTAGCTGTGAATTAAATGACTATTTGGCAGTTAAGGGGAGAGTAACAATACAGTTTACTGGTTCTGTGAACTTCTGGGAAGCCAGTCTTCAGTCTACTTGGCAGATTGTCTACGAGAATATTATGGAGTACAACATTGTCACTTTGTTAACTATTTAAAAGGAAAGGAAAAGGAGTGTTAAAAAAATGATTGAGTGAACTCAAGATGAGGATATCAGGTACATTCTTCAGTATCTCTTTCTCTCTTACTCCGGGGTGGGGCTAGAGAGATGGCTCAGAGGTTAAGATCGCTGGCTGCTCTTCCAGAGGTCCTGAGTTCAAATCCCAGCAACCAAATAGTGGCTCACAACCATCTGTAATGGGACCTGATGCTTCATGCAGATAGAACACCATGTATATAAATAAATACACCTTTAAAAAATATAGACTAGGATACTTTAAGATTACATAGAATGAACCACCTCACTAGAGACTGTGGATCCTAACAATGTATCTTGAATATTTTAGCAAACTCTTCTCATTTTTCTCCATTAACCTAAGAGCATAAATATATAAGAAACACCAACCTTAGCTTTTAATACTAATAATTTCCTATGGTCTCATCTTTGTGGACCTAAGACTCACAGTGAAGAATAATACAGGATATACTTAATGACAGCAGCTGTTTTCCTTAAGAATTAGATTAGGATTCTTTGAGATTGAACACTGACCTTCAGTGACTTTGTTTAGGGCTCCAAATGTTCTCAACGATGTAAGCCAGAAATGTTTGATGTCTTGTATGCATCCCAGTGTTACCAAAGGTGTCTTTAAAACTGCACACGTAGCACCCAAGAAAAAGCACCAAGCCTGTCTACCGTTAATCCCAGTGCTAGGGAGGCAGACAGGAAGATTGGTTCTTTCTGGCCAGTTGGTCTAGCCACATTGGTAAACTTCAGGTTTGGTGAGACACCTTGTCTGAAAGTAAGGAGGAGAGACAACTGACACCAACCTATGGCCTCTATGCCCAGGCACACATATGCATGCATAGATACACCAAATGTGCACAGACAAGCACATGCATACACACAAAGCCCATTCCTGAGCCCCATTAAATAATAGTAAAAAAAAAAATCCACACATGTGTGCGTATGTGTGTGGGGGGTGGGCACGCCCATGTGCTCATGTACATGTGTGGGGCCATTCCTATTTTATGGCGCATGTGTAGAAGTCAGAGGACAACTTGTGGGATTCCATCTCCTCCCTTCATGGGCCTTCAAGGGTTAAACTCGGCCCCAGGCTCCTCCATCAGTGAAGCCACCGGGCTGGATCAAGCCGCACACTTTCTGAGCTATCATCCTTAGATGATTGTTTTGCAGCCTGCTCCTTGAATTTGCACAGTTACAGATGGTTAAGACCAAGTGCTAGGAACTACTCTTGTGATAGTTGTTCGAGATAAACCTACCTCTTGACGATAAGCATGTCCTCTGGGGAAATGAGGGTGAAAGAGTGACAGGAATGCACGGTACACAGAAGAGGGGTGTGTGCTGTGGGCAGAGACGTTCATAGTGGGTCTCAATGTTACTGAAGCTGTCATAGCTGCCAGTCACAGCTGCCAGGTGATGTTTACCTGCTGGGCTTGCTAATATTCAAATAGTGGCCACGGACTCCATACCTACTCTGCTCGACACCGCTCTTACGGTTCACGCAAATGAGAGTTGTCCAGGAATGCGGGAGGTAGCCTTGCACCTCTCGTGGGCAGCTGCAACAAATGACCAACCAGGTCAGTCCAACATTTCTCCATCTTTTAGTGTCTGAGAGAAGCTAGAAGAATGGATTTCATACCAGACTCCACCCTCAATCTACTAAAGACCCTGAAAAACCGTCCGCACACACACATAGTTGGACTTGGACTACCTGCCGTCAGTCAGGAGTCCTTTTTTAGAGTAGTGCTATCCCCAAGGCGAGCATCAGCATCATCACCAGTGCAGACCTCACACTGATGCCAACTGCCTGGGTCCACATCAGCCTAGCAGATCGGAAGCCCTGGGGATAGCACCTGTTATCCTCCTCCAATACGCAGGGTGGTTCCAGTGTAAACTCAGATTCGAGACCCACTCTTCAGTAGTGTGCAATTTCCCATTACCGTTCCGCATGAGGACAGTAAAGACATAAGCTCGTCAACTCTAAGTTCCCGAAAATATCTCTACATAGAAATGTCAGGCATGAATTACTCTCAGTGTACGGCTTTTTGCATCTTTTGTGAGAGTCAAAGTGTTGATTAAGTTTTTGCTACCTTTGCATCGGACATTGCAAATGACATTAACGGGAGCTCTGTTTTACAATTTGACCTCACTAAGACATGTTTGACATGCTATTTACTGGGTGATTCAAATTTGATAAATGCCATGTGACCTTCTAAAGCTTTGATTTCAAATCTTGCCAAAAGCATGACAATAAAGAATGCCTGTTAGGCTGGGTACCTGCCCATCATAGGCAGCCTGACCTATGTAATGGGTTCCAGCATGGATTATGTGGTGAGACTACCTCAGCAAACAAAGCAGATATGCAAGGTGGCTGTCCCTCAGTGTTCTTGTGTGCACAAGGCTTTCAGACTGTGTGTTCTTTCAGATTTTTGGAATATCTCCACATATGTAATTAGGGCTCACTTGGTGGTCAGACCCAAGTTGGCGCCTGCAGTCTTTCCTTATGTGTGTACATTATACATGTACACAGGCAGTTTTATGTACTACATTTTACAAGACTTCACTTGTTTGCACCCCATTCTGTGTGTGGAATTTGCCATTTTTATCATAGGTGTTCAATTTTTGATGTTTTAATTTAGGCATGTCTCCTCATTTTTTTAAAAGATTTATTTATTATATATAAGTACACTGTAGCTGTCTTCAGACACACCAGAAGAGGGCATCAGATCTCATTACAGATGGTTGTGAGCCACCATGTGGTTGCTGGGAATTGAACTCAGGACCTCTGGAAGAGCAGTCAGTGCTCTTAACCGCTGAGCCGTCTCTCCAGCCCATGTCTCCTCATTTTATAAACATTTTCAAAAATGAATTCCGTTGACTGGAATCAGTACTTTAGTGTGATTTTATGTTAAGTGTGGATTCACTGCTAATTGAGTTGGGTTTTTTGCTCCTTTTTTTTATTGGATATTTTATTTACATTTCAAAAGTTATTCCTTTTCTTGGTTTCCTGGACATAAGTCCCCTATCTCATCCCATCCCCTTCTTCTATAAGGCTGTTCCCCTCCCAACCCACCCCGCTTCCCACCCCACCCACGACATTTCCCTACACTGAGGATCCAACTTTGGCAGGACCAAGGGCTTCTCCTTCCATTGGTGCCCAGCAAGGCCATTCTCTGCTACATATGCAGTTGGAGCCCTAGGTCAGTCCATGTATAGTCTTTAGGTAGTGGTTTAGTCCCTGGGAGCTCTGGTTGGTTGGCATTGTTGTACATATGGAGTTGCAAGCCCCTTCAGCTCCTTCAATCCTCTCTCTAATTCCTCCAGTAGGAGGTCTCGTCCTCAGTTCAGTGGTTTGCTGCTAGCATTCGCCTCTGTATTTGACAGGCTCCGGCTTTGCCTCTCAGGGGACATCTATATCTGGTTCCTGTCAGCATGCACTTCTTAGCTCCATCCATCTTATCTAGTCTTGGTGGGCGTATACATATGGGTCACATTTGGGGCAGGCTCTGAATGGCTTTCAGTCTCTGCTCCAAACTTTGCTTGAGTTAAGTTTTAATGCTTACATATTAATGCTAATATGTGTCCCTCTTGTTAGAATGTGGAAATAATTGTGATCTTTATTGCTGTCTTAAAGTTCTTATTCTTCCTCAGATACGGTCACTTAAATGTCCCTCGTACTCTGCTAATCAGATAATATCAGACGAAGAATTAATGCTACACCTACCTTACTTATGAAAAAAATTAATATACGATAGAGTGCTTAAAATGCAATTTTAGAGAGGCTGGAGAGATGGCTCAGCAGTTAAGAATCCATATTGCTCTTTCAGAGGCCCTGAGTTCAGTTCCCAACACCCACACAGCTGCTCACAACCATCTAACTCCAGGTCCAGGAGATCTCAGTGCTTCTTTGACCATTCCATGCACTTAAATGCATGTGGTGCACATACATAGAATCAGGCATACATACATACACACACAGACACAGACACACACACACACACACACACACACAGAGATGTAAAATAAATACATTTAGAAATAATTGTTCCTTTAAATATTTAACTGTTGACACTGTCTGAAGTTGGAATAATCTTATTTAAAGTTCTGGAGTTTGAATTTAAAAAGGTATTGATTTAATAAGTTTTTCATTTAATATTAATGAGAACACATTTCTATTCCAGGGTAAACCAGACCTGAACACAACATTGCCAATTAGACAGACTGCATCCATTTTCAAGCAACCAGTCACCAAAGTCACAAACCACCCGAACAATAAAGTGAAGTCAGACCCTCAGCGGATGAATGAACAACCACGTCAGGTAAGGAGCCCTTTCGTCTCCAGTCATCGTTTCCAGAAAATTCTGGTATTCTTACCAGGCACAGTTCGGGTAAATTCTGGTTAAATTGGAATGCATTTGGAGGAATGTTTTATATCCAGTCCTATTGTAGAGAATAGCCATAATACAGGACTTAATAAAATATTTTAAAGTGAATTAGAGTGAACGGAAGCAATAGCATTGGCAATGGCTTTAGTTTTCCTGTGTTATAAAATGCCTGAGGCTCGGTTGTCCTAATCTTAGTTTTTTTTAAAGACTATTTTTGTAGAGATAGTATTAACTAGAAGGCTTAATCATGGAGCTTGTGTTGTGTTTGGTTTGAAAACATTTTCTATTATTTGGAAATTGCTTCTTTACCCCTCTGATTCTGATTTTTAATTTCGAGGAATCTATATCAAACCTTTTGAAAAACTGAATTAGATACAGTTTGTCAGTATGGGTATATTACTGTGAGATCCGTTTTTGTATAAGTTCAATGCATTTTTCTCTTTCTTTATTTCTTCAACTTATATCTACCGGAAACTTTTCTTAGTATTATCTGAAAGGCTCCCCCGTTGCTAACGAAAGTCCCCCGCCAGGGACGAAGACTGTATAGCCTTCCAGATGGCTCTGCTGGTCCTCCCTCTTGTGGTCAGAAGTTAGGTACTCCATGAACTTCAGTCACGGCTGGGGTGAGAAGGTGGAGGGAGACACTGTATTTCCTCTCTTCTCTCTGTTTCTTCCCACTTTCCAGCTAGAAGCTCCGATTGGCCTACAATGAGTGTCTCTTGCTTGAATGCTGTCCACTCCATCTTGTCATTTGATTTGTTTTACACCAGTCCTTCAAGCGTTTCATCCTCACATTTCACAAAGGACTGGGCCAAACCCCTCAGACATTTGCTCTAGAAGAAACTACAGGAAAAAAAAAAAGTCAGTTCCCACATCCTCTGCAGTGTTTTTTCCTCTTCAGGTGAGCCAGGAAAACAGAAGATGTTTGGAGCCATTGGATCAACATCTTGCTATAGATGTCTCAAGATTTGAAGTTCTAAACTTGCTTTACTGTTGGTCCCCAAGAGATTCAACAGGGGCCAT。
2.4差异表达circRNA作为miRNA海绵的功能分析
circRNA的一个重要作用机制是发挥miRNA海绵功能,结合miRNA反应元件(miRNAresponse element,MRE),调控基因表达,影响疾病的发生、反应发展。
利用预测软件对上述circRNA与miRNA的结合位点进行分析,结果显示本申请保护的circRNA有19个MRE:
rno-miR-132-3p、rno-miR-219a-2-3p、rno-miR-466b-4-3p、rno-miR-466b-3p、rno-miR-466b-5p、rno-miR-146b-5p、rno-miR-466c-3p、rno-miR-6216、rno-miR-206-3p、rno-miR-3473、rno-miR-466b-2-3p、rno-miR-293-5p、17_41438、17_41409、17_41456、17_41426、17_41422、rno-miR-212-5p、rno-miR-127-5p。
采用Cytoscape绘制circRNA/miRNA关系图,结果如图1所示。
实施例3
3RT-PCR验证对照组和模型组中circRNA相对表达量。
1.模型建立
具体方法同实施例1,其中,假手术组(正常对照组)和急性肺损伤组每组8只。
2.实验方法
2.1组织总RNA提取
参考实施例2。
2.2引物设计
针对circRNA的环状闭合结构,设计背靠背引物(divergent primer),GAPDH作为内参,送往引物合成公司合成;
circRNA引物:
上游引物:5’-TGGTCCCCAAGAGATTCAACAG-3’(SEQ ID NO.2)
下游引物:5’-CATCATCTTGCCGGTTCTGAAG-3’(SEQ ID NO.3)
目标基因扩增长度:128bp。
2.3反转录
按照PimeScriptTM RT reagent Kit(Perfect Real Time)RR037A(Takara)说明书配置反转录反应体系,首先将各试剂进行瞬离,使用移液器依次添加至去RNA酶的EP管中,充分混匀,将反应体系置于T100 Thermal Cycler梯度PCR仪内使RNA逆转录为cDNA,逆转录条件为:37℃15min,85℃5sec循环,最后4℃保存。
2.4RT-PCR验证样本中circRNA的表达情况
按照SYBR.Premix Ex TaqTM(Tli RNaseH Plus)RR420A(Takara)说明书配置RTPCR反应体系,具体见下表;首先将各试剂瞬离,使用移液器依次添加至去RNA酶的EP管中,混合均匀,置于ABI 7500PCR仪进行qRT-PCR反应。
表2为RT-PCR反应体系
组分 体积
2x S6 Universal SYBR qPCR mix 5μl
上游引物 0.3μl
下游引物 0.3μl
cDNA模板 2μl
ddH<sub>2</sub>O 补足至10μl
反应条件:预变性(95℃,30sec);变性(95℃,3-10sec);退火&延伸(60℃,10-30秒),循环数为40;融解曲线使用仪器默认程序即可。
2.5统计学分析
利用Graphpad Prism 7.00软件对实验数据进行统计分析;数据用均值士标准差表示;P小于0.05代表差异具有统计学意义,所有实验重复三次。
实时定量PCR扩增曲线整体平行性好,表明各反应管的扩增效率相近,扩增曲线拐点清楚,极限平而无上扬现在,曲线指数期斜率较大,说明扩增效率较高;样本扩增产物溶解曲线为单峰,表明扩增产物唯一,是特异性扩增;RT-PCR的相对定量公式:2-ΔCt×100%。结果显示:circRNA在急性肺损伤模型组中表达量明显高于正常组,差异具有统计学意义(P<0.001),是正常组的约1.8倍(具体结果见图2),在急性肺损伤的20例肺组织中70%表达趋势符合预期。RT-PCR验证实验结果与数据分析结果基本一致,显示circRNA是很好的辅助诊断分子标志物,可能具有很好的临床应用价值。
实施例4
1.研究对象
选取2021年3月-2022年3月10例ALI患者为观察组,同期10例呼吸内科诊断肺炎患者为对照组,两组年龄18-75岁。
2.纳入、排除标准(1)纳入标准:年龄≥18岁;观察组符合ALI诊断标准;接受支气管肺泡灌洗术患者;无肺结核。(2)排除标准:长期应用免疫调节剂者;长期使用激素者;白血病者;伴有恶性肿瘤者;妊娠期、哺乳期女性;未做支气管肺泡灌洗术者;急性心脑血管疾病者;肝肾功能严重不全者;药物或酒精依赖症者。
3.检测方法:两组均行支气管肺泡灌洗术,通常于局部麻醉后将纤维支气管镜插入右肺中叶或左肺舌段的支气管,将其项端契入支气管分支开口,经气管活检孔缓缓注入37℃灭菌生理盐水,每次30-50mL,总量100-250mL,不应超过300mL。每次注液后以-19.95~-13.30kPa负压吸出,要防止负压过大,过猛。分别收集于用硅油处理过的容器中,容器周围用冰块包围,并及时送检。记录回收液量,至少应回收30-40%以上。
合适的BALF应要求:(1)达到规定的回收比例;(2)不混有血液,红细胞数小于10%;(3)混有的上皮细胞小于3%。采用酶联免疫吸附法检测sTREM-1表达,采用实时定量PCR检测miR-127-5p、miR-3473、17-41409、17-41422表达。
4.统计学分析
利用Graphpad Prism 7.00软件对实验数据进行统计分析;数据用均值士标准差表示;P小于0.05代表差异具有统计学意义,所有实验重复三次。
实时定量PCR扩增曲线整体平行性好,表明各反应管的扩增效率相近,扩增曲线拐点清楚,极限平而无上扬现在,曲线指数期斜率较大,说明扩增效率较高;样本扩增产物溶解曲线为单峰,表明扩增产物唯一,是特异性扩增;RT-PCR的相对定量公式:2-ΔCt×100%。结果显示,人体急性肺损伤中miRNA表达趋势与大鼠急性肺损伤中miRNA表达趋势相同。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Figure BDA0003543147190000191
Figure BDA0003543147190000201
Figure BDA0003543147190000211
Figure BDA0003543147190000221
Figure BDA0003543147190000231
Figure BDA0003543147190000241
Figure BDA0003543147190000251
Figure BDA0003543147190000261
Figure BDA0003543147190000271
安徽医科大学
一种新 circRNA、试剂盒及用途
3
SIPOSequenceListing 1 .0
1
9773
DNA
人工序列(Artificial Sequence)
1
ccaagtggtaagaagttcagaagtaaaccgcagctggcgagatacctgggaaatgctgttgaccttagcagttttgacttcagaaccggc
aagatgatgcctagtaaattacagaagaacaaacagaggctgcggaacgatcccctcaatcagaacaaggttggtaaatgtacttgtaa
tgtggacatgcacttcctaggctctccaccagtgtttcatgttgtgtttgggttgtgatcttggttggctgaaaatgtctctccctactacagagcctt
ttaaaacttacaagtgagacttatgtttctatatttggaagtgcttggaaaaatgtgttaagtaattgtgcatagtagaaaacaatatttcagtatg
tcattaggccaacatgggcaccaaccacactttgtgactttctcttttttctttcattcattcattcattcattcattcattcattcattcattcatttttcaa
gatacggtttctctgtgtagcccttgttatcctgaaactcattctgtagaccaagctagcctgtaactcaaagatatccctgctttttcctcccaagt
gcttgtattaaaggcgttcatcatcaccatttatctggcttgtttttttcttaatttttttttctatttcctaaaaagaggcaacattcccacatagtgtatt
gtgtctaattttatagttagttcagaagttgtgcctttgacggtgatgacacctacccgtagacatcactgttctcgtcaggtttcacgagctctaa
attttcttgaacttgttgcttgactattctgtagcaatataaataagttacatttgaatatgttaatttaatttgaggctttagaatctttttttttttttaaaa
gcttctgttcttccaaggacaactggccatgtatgacccacagatgacgcattgccttgcatggttcctctaagtatgttctcacctcagcactg
agacaggagctgaggtgaagtcactgcaggttcctcagggatttcagggactttgttatcagttgtgaaagggcttcatttctgtacatttagg
agtctgtctgtgtgttaccatcaacacactttctccctcaggcttgtgaagttcagggtgaaaagcagaggcatttcttaggctctgactgctgtg
gccggccagagcctcagtgtgcagtcctgaggaagcaggctgtgggctcaggcgggcgggctatgctgggtttcagcagctacactcac
tcacacacaacattcttactctgaaggcccgaggccttttgtagaattgggcaagaaaactcctatagctttatcatgagaaaatacagtgg
gaatttacataaaaacatttaacaaagtattgacccatgctattttcctttttttcaaactgccctttccttccttaaggggcagccaccttctgagc
accgagccatcctgcttaacatggcgtccggtgtaggaagctttctggttcaagctctttatctcatttttttgtttttgtttgtttttgtttggaatacac
aaactcacacacacatcatgtgcgtgtgtgtaatatattgatggatatagcgactacatttttctagaactgctgctgtaaactctagttatagca
ctgcctgcatgccttagaaggacttacatatttatgaaatgaagagaatgtgtttagattaccctgctgtgcccagaatcacagtttagcctcct
ttaatgtaatttgaagctttacgtcctgacagttatggttcgttaaaccccaacactaattggtctctagtttgtgtgcacccttctgctctagccgct
ctggaccgctcttcaccccgcagcatggcatgcgctttcgggatctgcttgcttctgtgctgtttcctctgcttggaatgtgctcccctccccctca
cccggtgacctcctcagctgaggctcagctccattgcctgcataccggggaatcctgtccctccctccgagatgaccatgtgcttcagctag
actgtgagctccacgagagcaggactctttgctttgttgttttgtgtagttgccccaaaccttgcacgtagtagcctattaaataaatactgcttta
ctctccatttgattctagaagggtgtagtgataataaatgcttattcaataaatgtgtacaacacgcgtgtggaggtgccggttgttttcattgtttt
ccactgtgtgaaggttgtgctgcctggtctaccttgacctgagttttgttttagggaagtagccacagttttacaagcagacttgctttgggagtg
acactatcattccaagcaggaaaatgtggtaaaatgaagttgtttttcatgacgcgctgagtaaagaaaactgggaatgacaagtggcag
acagaaatctcagtatgcagcaagcttggtcaggggtaattactcattgggtactttcctttttttaagtttttacaagaggttttcttcttagaactg
gggatatagtcaacaaggaaggaaggttttaaacaggattaaccgactgtaagttgatcttaacgtctgtcttctgtattattgctaatgaatg
gttattttcaagtatcattagaaggacccctctgaagatcttcaccagcgcccttcagtcatcctccggtgggcgggaagggagctgggcatt
gcccttggattaacacactgcaggttttgtacctgttttgcttttctcaaatttagtcttaatctagccctcaaagttgattgcattcttgatttgattac
actttattgatttttcttgctactgctataattatttgcagacaacctatctctcaagctgataaaatccatctgagataccaagttactgaggctctc
actagggttaatgggagcggctgactcagaataataggaagtggccaacttgagtgtggtgaagtcatagcagtttgaccccagtggagc
attctgggatggaattgtggtagctttagccacacatgtgaccaatacgcagttacatatgcgtggactccttggatttctagaatgagaaggc
aaagcttcaaatactcacacagacacacacacacacacacacacacacacacacacgcacacacacatttagacttttaagacatattt
caaatttcagagataggatttgacattttaaggaggcagtggagacaagatggtaatttcgggtgactgagatggctgagcagttgaaggc
ccttgctgccaaatctgatgacatgagtttcattcccatgacccatgtaaagatggagagagagagagatcacacacacgcacacacata
tacacatgtacgtacacatgcatgcacacacatgcacacacatgtacacagatgcacacacatacacatgtatacacacatacacatgta
cacacacatacacatgtacacacatgcatgcatacagagtgggggagggagactgggaggagagagaaaatataaacaatataaaa
ctaagataatgtctaaagctgacgtggagatattctaggatgagccgcattaggttgtttgtacaaagcaggcttagggaactttggaaactt
ggttctgttagaaattctacattaagctgaattccttatgtttctgtcttttaatactacagtattaatggaatatcataacgaagctgcagaactta
aatgcacatgtcctgaccttgatgtggtctgcgatagattttgcaggttgcttacaatagacatgtggacccagtcttcctgagtgaacttgaga
gcactgctgtagccttagaaggtgccactctgtgcctggcctgttcctctgggtgaggtcaggtctgtgtcagatctgccactcttcatttctcatg
ggccatctcctgtagtgtgcatagtcagtatgtcattgtgcatacaggcacagacttagattatgtatgaccgactgtatcctagatttttagaca
cacggagaggatacatgtttcaattatcctcatgaaataataaaaattgcacttaagctcagtagtgtaatttggaggcagttactgtgtagct
agtggatagctagcctttgggttaggcagcatgcactgtggagaagcatgcagcgtgcagcattgcaagcgggcgaagctggaaaggc
acagtgctagctgggctctttgagtccagaaagcagcagccctgaattagtgctgtggcaggaggcctgggaagggggaatcgagaag
tgagtagatttaagtgcctgctggttacagcgaaagggaattgatgcttcctaaaattgtggctttggtcactgctgcagtttgggtatactttgtc
tcctaaaagttcttgtctggagacgtggccctcagtactgtgattttgaagcggatggggtggcccagtggaaagtgaccaagtcatagggt
tccatttttataatggattaacgccacccttggagggagcattgtggctttcacaggcattcctctaacggagagctgtaataaaaagatcaa
gcccagccttttccttctctcgcttctctgtttgcatacctgtccccttgctggcaccatgctgtctagccaaataaagccctaagttgcctgagcc
ctaggtattttgcttagcaacagccagttgagtctttcaagaaatagaatggctgctgctgaagggttgaccaaagaagacaaaactttattg
agtttgacattttaattacccttcttttgagacagggtgtttctacataactttcactgtcctggaactcattatgcagacccaggccagccttgaa
cacagatccatttgcctctgattactgggaactgagattaaaggtagcaaatatcagcataggaagctttaattagctctgagcactaggtttt
gtggggacagaagccaggttggattgtaatgtgaaattggacagcaaggacagctattcagtaaattttcataggtaagtttgagagtcact
gaataagagaggaaagagacgacacttcagttcaaagattggaatggttaaaaacatgggtcgtgagagaaggaattgtggagatcag
aaaactgtgttctcagatagcaaggccatgtaactacactagttagggaggaatgtgaaaggcacaggaaactaaggaaaagggata
gtcaactgatggagatttgggggtccgaaggagggaatggcagccctgagttgtgagctgcagaccggaggcttcattgagatctggaa
ataagagttgctgcttttgacccagtgtaactaatggcaggtaagtgaggttgaacaggggaatggtccaaggacagatggaggtctcca
aaaatgaggacagagtttgggtttagaaggacaaaacataatgaactaaaggatggtgtgtgtgtgggggtgtgtgtgtggaggagtcag
agactgggggctataaagaagctgctgctttggagggagaaacaatggagaaagtctagaaagcagtagggagagcagaaacaac
ctttcggatccctagatgcattgtctcaaggggtcagagaaaggggcctgagtctaatgactgggactgcatatagagaactgagctttcttc
tcgctcccagttagctgccctaacacaagctcactcccccactaataaacataatttaaaaattaaaagagctctggatgtagctcagggat
agtgtgaacttagggattgtttcttttatattaataaattggagcagacaatcttccttttcatgacaataattttaatgcagatcatacagattaaat
ttaattacattatttttcgtttagtacttttaagttcaagacagaaataagattattcaggctagggctgttcgatgtagggctaaatgtgtaatggc
attttggctctaattagcttattggaaagaattttcaaagttgaggcaagcatgattctaaatttgagacttctgtagaggaagtcccaggagat
tctacttgagggggatataattgatcaattaaaatagtgcggtgcaatgtgctaagtaatacaaaggtgactgggtgatattttaggtagaatg
ttgatgacaagtttctccgctagtaaggtttagatgagttttgaatggcaagtgaccattctccaataacttgagagaaaagctttctatgcgaa
ggaaagaacttgtgcaaagtctttaaggaaaggtgcaccagtatgtgagtgaggacagaaagaaggggaggtgttggagtgaactgag
tggagagcggaacccagatgaggttgaagacgacgacgacgacgagctgcccatagtacagggtaatacagaaaggcccaggctc
ggtgcagttacacgttaagaatgtattgtagggtagcagaaacaggccagggtttgagttgggatctgttgaggactactgtacttgtccagg
caggtgacaatgacttaggcagtgcatattttatgaattaaaaaaaaatagaaaagaagactggtcaactggtcactatttttttccccaaag
agtttatagttttatgtgtacagaaatatccttaataaatgggtaaaggctattttccctaatgaataaagtcattattaattagacgccatcattgc
tgctaattagccatttatttagaaatttgggtataataataatagtaatagtaacacaagttataagcttgctggtgagagcactttggtcagtaa
agtgttaggtttgtccagcttttggggattcacatgtatcccactgtggtagaaacctctgagagcacctggacttggatgtcacattaataatg
gaggtcgatttgaggatatggttgtgtgtgtcatgacattcatgtggttttatttggctactcatttctgctaatgatttcattaaattttatagcccaatt
ttccagacctagaatctggggccattgtgtcatacaaaaaaccgcttgtgtgacttttcatagttctcccaagaatgcatacacatgtcaaaca
attttctattccctggatctagagatacaggggctgtaaactgacatggttccaggaaatgaacttgcatcctgcaagagcagcaagtgctct
taattgctgagccatctctacatccgtgtgtgtgtgtgtgtgtgtgtgtgtgttcgagagtgtgtgcgagcgcctgtgcctccctgcctgcctacag
catttatgtgcaccacatatatgcaagagcccacaaaggtcagaagagagtgttggatcccccggaactggagttaaaagtgtgagtcac
catttggatgctaggaactgaacctgggttctgcagaaataacacgcacagaagccatctttacagatgtacttttaaaaagctatgatgaa
ttgccaggcagcttgcattgtgggcgtttgatttttgtgaaatttgaaattgctacttgaaaataaccttgcttctactcaagcacatgcaagttata
actgccctggaaaaccataaaaggttacgtgtcttaagtttctgtagcatgcctagtagtgtgttaaaggccggtatttattcaggattgatttgc
caagacaatcacacacttttttactgatgatcttcatctctctgccttctggaatgtaagctctaaggcagggactgtttacaaatgacattttcag
cttcgggttaggacccagcacacagtagacacagtctttgcacaatgactggctaagactgtatcagtgtcattatcatggccattttgtttgat
ctgtagaagagttgcagtaatcatcctgaccaacggataagggaattgaccatagtggcagcgagtctttgcttccccattagggtataaat
atctctggaacatgttgtgtactcaaagctacagaacgaacatggtacatggtgatattttacagtgtcagttctaaaggagcacttagggta
agcagagccacaattttcaccctgcgataaaataaaatttcaaagtgaaaagttattgtcagtgtgaaagtaaaccttctatgctgtggttata
gggttaagctatctttcatccagcttttctccaaacctgactgacagggctggagatggctccagggttaagaggacctcctgctcttacaca
ggaccagggttcagttctagcacctgcaaggtggctcacagctactttataagtgcagttcctgatactctctatgcctctgcaggcaatatga
ccaagtgatacgcacagaaacacgcaggcaaacacattcatacacataaaataaagataaattttaaaagtctgtctaaagaaggtgat
acatagagtctaagtcactatgctgtaacaggtaaatttctcatgcatatctatctgtaagacttcttgtggggttggagtcaaacccagggcttt
gcatgctatgcaggcactttcccactgagccatgcccatgctttacacacgtgacctggagggaactgaggtcagcatatctttgaagcttc
ataaactgcatggtttccttcagtctctgaggacacctgtatggatattttttcctccacattttccccctagcaacaacctttcatattatagatgtg
catgcttctcacatgtgtgtagtgtcagaatggcagtcagtgctgtgctgtcgatagaggaacagctggaaatactggattgaaatgaatca
cttggtaacaacttttcccacaaataaaactctgaacaaaatgtagggaactttatgtatctgtctactgattattaagggttttttttttttgatgtctt
acaatcaaattgtcttaaaatgtgatattttaatacaaactcttaaaagcagttcaaggtctgagtcacagggtgaatgcattcttcccagtcat
gtgaccaggacttttcagtgccacctcatctagaataaacggaaataggaatagaattgatgttagcaattagtaacacttatcaaagaac
atgaaggtatttaaaaattcttgcagtcaggcatacttgagtgtgcccataatccagggactggggagggcaaggcaggagaaggatcat
ttgagaccaggggttgggaggccagcctaggcaatgtagcaagaacctatttcaaaaacaagaagtagaaaaggccccaccagctttc
ccttggagctgtagctcatttctgaagttaggtatgtttagtagttactttaaaattgtaatacaccatgtttggtaaaacagtattttgttttaaacat
gagagctttatatgatcacaggaaatagaaagataccactaaatttcagttggataaaatactaattaatattaatagtactgataaaatatc
actaaagatttttttcaagtctgaaattggaaataactttggaaatgacattttttattcaaaaacaaaatgtagactgctgacatgttccctcgtg
tgtagaggatcgatggctttttagtgtgttattgtgtaactaggcagaactaagacagttccacttgtaattacctaccttaagtaaaatggaaa
ctgatggcagctttagagggcggtgagctgcatgtactttgaacattctgaggaggcagggtagaaatgccggcgggtgctggtttataga
acagttctacaacctgtgtctcggtgacccgttccacagtactgagacccatcccttcccagccactttcactgcgtggaccttaagtcttaagt
cacaggtatctgtggaaggccactgaagaaagtaaaaacaaatctgcttctttaacaggacatatttttagagttttaaagttcacgagctttt
gactagagggctgggctggtttataacattgcagtgagtttgctggttaagtttgtaatgtaaaggaacttcactttttttatatttaaagaggattt
cagttttatgagcagctgtaattgtgcttcacgcccaggtgatggtgtttaatgcccaggctcatggcagagtgccagtggtctaggcaaact
caggtagcaggtagctgtgaattaaatgactatttggcagttaaggggagagtaacaatacagtttactggttctgtgaacttctgggaagcc
agtcttcagtctacttggcagattgtctacgagaatattatggagtacaacattgtcactttgttaactatttaaaaggaaaggaaaaggagtg
ttaaaaaaatgattgagtgaactcaagatgaggatatcaggtacattcttcagtatctctttctctcttactccggggtggggctagagagatg
gctcagaggttaagatcgctggctgctcttccagaggtcctgagttcaaatcccagcaaccaaatagtggctcacaaccatctgtaatggg
acctgatgcttcatgcagatagaacaccatgtatataaataaatacacctttaaaaaatatagactaggatactttaagattacatagaatga
accacctcactagagactgtggatcctaacaatgtatcttgaatattttagcaaactcttctcatttttctccattaacctaagagcataaatatat
aagaaacaccaaccttagcttttaatactaataatttcctatggtctcatctttgtggacctaagactcacagtgaagaataatacaggatata
cttaatgacagcagctgttttccttaagaattagattaggattctttgagattgaacactgaccttcagtgactttgtttagggctccaaatgttctc
aacgatgtaagccagaaatgtttgatgtcttgtatgcatcccagtgttaccaaaggtgtctttaaaactgcacacgtagcacccaagaaaaa
gcaccaagcctgtctaccgttaatcccagtgctagggaggcagacaggaagattggttctttctggccagttggtctagccacattggtaaa
cttcaggtttggtgagacaccttgtctgaaagtaaggaggagagacaactgacaccaacctatggcctctatgcccaggcacacatatgc
atgcatagatacaccaaatgtgcacagacaagcacatgcatacacacaaagcccattcctgagccccattaaataatagtaaaaaaaa
aaatccacacatgtgtgcgtatgtgtgtggggggtgggcacgcccatgtgctcatgtacatgtgtggggccattcctattttatggcgcatgtgt
agaagtcagaggacaacttgtgggattccatctcctcccttcatgggccttcaagggttaaactcggccccaggctcctccatcagtgaagc
caccgggctggatcaagccgcacactttctgagctatcatccttagatgattgttttgcagcctgctccttgaatttgcacagttacagatggtta
agaccaagtgctaggaactactcttgtgatagttgttcgagataaacctacctcttgacgataagcatgtcctctggggaaatgagggtgaa
agagtgacaggaatgcacggtacacagaagaggggtgtgtgctgtgggcagagacgttcatagtgggtctcaatgttactgaagctgtca
tagctgccagtcacagctgccaggtgatgtttacctgctgggcttgctaatattcaaatagtggccacggactccatacctactctgctcgaca
ccgctcttacggttcacgcaaatgagagttgtccaggaatgcgggaggtagccttgcacctctcgtgggcagctgcaacaaatgaccaac
caggtcagtccaacatttctccatcttttagtgtctgagagaagctagaagaatggatttcataccagactccaccctcaatctactaaagac
cctgaaaaaccgtccgcacacacacatagttggacttggactacctgccgtcagtcaggagtccttttttagagtagtgctatccccaaggc
gagcatcagcatcatcaccagtgcagacctcacactgatgccaactgcctgggtccacatcagcctagcagatcggaagccctggggat
agcacctgttatcctcctccaatacgcagggtggttccagtgtaaactcagattcgagacccactcttcagtagtgtgcaatttcccattaccgt
tccgcatgaggacagtaaagacataagctcgtcaactctaagttcccgaaaatatctctacatagaaatgtcaggcatgaattactctcagt
gtacggctttttgcatcttttgtgagagtcaaagtgttgattaagtttttgctacctttgcatcggacattgcaaatgacattaacgggagctctgttt
tacaatttgacctcactaagacatgtttgacatgctatttactgggtgattcaaatttgataaatgccatgtgaccttctaaagctttgatttcaaat
cttgccaaaagcatgacaataaagaatgcctgttaggctgggtacctgcccatcataggcagcctgacctatgtaatgggttccagcatgg
attatgtggtgagactacctcagcaaacaaagcagatatgcaaggtggctgtccctcagtgttcttgtgtgcacaaggctttcagactgtgtgt
tctttcagatttttggaatatctccacatatgtaattagggctcacttggtggtcagacccaagttggcgcctgcagtctttccttatgtgtgtacatt
atacatgtacacaggcagttttatgtactacattttacaagacttcacttgtttgcaccccattctgtgtgtggaatttgccatttttatcataggtgtt
caatttttgatgttttaatttaggcatgtctcctcatttttttaaaagatttatttattatatataagtacactgtagctgtcttcagacacaccagaaga
gggcatcagatctcattacagatggttgtgagccaccatgtggttgctgggaattgaactcaggacctctggaagagcagtcagtgctctta
accgctgagccgtctctccagcccatgtctcctcattttataaacattttcaaaaatgaattccgttgactggaatcagtactttagtgtgattttat
gttaagtgtggattcactgctaattgagttgggttttttgctccttttttttattggatattttatttacatttcaaaagttattccttttcttggtttcctggaca
taagtcccctatctcatcccatccccttcttctataaggctgttcccctcccaacccaccccgcttcccaccccacccacgacatttccctacac
tgaggatccaactttggcaggaccaagggcttctccttccattggtgcccagcaaggccattctctgctacatatgcagttggagccctaggt
cagtccatgtatagtctttaggtagtggtttagtccctgggagctctggttggttggcattgttgtacatatggagttgcaagccccttcagctcctt
caatcctctctctaattcctccagtaggaggtctcgtcctcagttcagtggtttgctgctagcattcgcctctgtatttgacaggctccggctttgcc
tctcaggggacatctatatctggttcctgtcagcatgcacttcttagctccatccatcttatctagtcttggtgggcgtatacatatgggtcacattt
ggggcaggctctgaatggctttcagtctctgctccaaactttgcttgagttaagttttaatgcttacatattaatgctaatatgtgtccctcttgttag
aatgtggaaataattgtgatctttattgctgtcttaaagttcttattcttcctcagatacggtcacttaaatgtccctcgtactctgctaatcagataat
atcagacgaagaattaatgctacacctaccttacttatgaaaaaaattaatatacgatagagtgcttaaaatgcaattttagagaggctgga
gagatggctcagcagttaagaatccatattgctctttcagaggccctgagttcagttcccaacacccacacagctgctcacaaccatctaac
tccaggtccaggagatctcagtgcttctttgaccattccatgcacttaaatgcatgtggtgcacatacatagaatcaggcatacatacataca
cacacagacacagacacacacacacacacacacacacacagagatgtaaaataaatacatttagaaataattgttcctttaaatatttaa
ctgttgacactgtctgaagttggaataatcttatttaaagttctggagtttgaatttaaaaaggtattgatttaataagtttttcatttaatattaatga
gaacacatttctattccagggtaaaccagacctgaacacaacattgccaattagacagactgcatccattttcaagcaaccagtcaccaa
agtcacaaaccacccgaacaataaagtgaagtcagaccctcagcggatgaatgaacaaccacgtcaggtaaggagccctttcgtctcc
agtcatcgtttccagaaaattctggtattcttaccaggcacagttcgggtaaattctggttaaattggaatgcatttggaggaatgttttatatcca
gtcctattgtagagaatagccataatacaggacttaataaaatattttaaagtgaattagagtgaacggaagcaatagcattggcaatggct
ttagttttcctgtgttataaaatgcctgaggctcggttgtcctaatcttagttttttttaaagactatttttgtagagatagtattaactagaaggcttaat
catggagcttgtgttgtgtttggtttgaaaacattttctattatttggaaattgcttctttacccctctgattctgatttttaatttcgaggaatctatatca
aaccttttgaaaaactgaattagatacagtttgtcagtatgggtatattactgtgagatccgtttttgtataagttcaatgcatttttctctttctttatttc
ttcaacttatatctaccggaaacttttcttagtattatctgaaaggctcccccgttgctaacgaaagtcccccgccagggacgaagactgtata
gccttccagatggctctgctggtcctccctcttgtggtcagaagttaggtactccatgaacttcagtcacggctggggtgagaaggtggaggg
agacactgtatttcctctcttctctctgtttcttcccactttccagctagaagctccgattggcctacaatgagtgtctcttgcttgaatgctgtccact
ccatcttgtcatttgatttgttttacaccagtccttcaagcgtttcatcctcacatttcacaaaggactgggccaaacccctcagacatttgctcta
gaagaaactacaggaaaaaaaaaaagtcagttcccacatcctctgcagtgttttttcctcttcaggtgagccaggaaaacagaagatgttt
ggagccattggatcaacatcttgctatagatgtctcaagatttgaagttctaaacttgctttactgttggtccccaagagattcaacaggggcc
at
2
23
DNA
人工序列(Artificial Sequence)
2
ccaagtggtaagaagttcagaagtaaaccgcagc 34
3
22
DNA
人工序列(Artificial Sequence)
3
tgttggtccccaagagattcaacaggggccat 32

Claims (10)

1.一种新circRNA,其特征在于:所述circRNA对应的DNA序列如SEQ ID NO.1所示。
2.一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述试剂盒检测样品中circRNA的表达水平,circRNA对应的DNA序列为SEQ ID NO.1。
3.根据权利要求2所述的一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述试剂盒采用测序技术、核酸杂交技术或核酸扩增技术检测样品中circRNA的表达水平。
4.根据权利要求2所述的一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述试剂盒采用二代测序技术、三代测序技术、探针杂交技术、基因芯片技术或荧光定量PCR技术检测样品中circRNA的表达水平。
5.根据权利要求2所述的一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述试剂盒含有与circRNA杂交的探针或扩增circRNA的特异性引物,特异性引物包括上游引物和下游引物。
6.根据权利要求5所述的一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述试剂盒采用特异的引物检测样品中circRNA的表达水平。
7.根据权利要求6所述的一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述上游引物的序列如SEQ ID NO.2所示,下游引物的序列如SEQ ID NO.3所示。
8.根据权利要求7所述的一种检测急性肺损伤的荧光定量PCR试剂盒,其特征在于:所述样品包括肺组织或外周血。
9.权利要求1所述的circRNA在制备治疗急性肺损伤制剂中的应用。
10.权利要求2-8任一项所述的试剂盒在制备急性肺损伤诊断制剂中的应用。
CN202210242614.5A 2022-03-11 2022-03-11 一种新circRNA、试剂盒及用途 Active CN114634932B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210242614.5A CN114634932B (zh) 2022-03-11 2022-03-11 一种新circRNA、试剂盒及用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210242614.5A CN114634932B (zh) 2022-03-11 2022-03-11 一种新circRNA、试剂盒及用途

Publications (2)

Publication Number Publication Date
CN114634932A true CN114634932A (zh) 2022-06-17
CN114634932B CN114634932B (zh) 2023-09-05

Family

ID=81948308

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210242614.5A Active CN114634932B (zh) 2022-03-11 2022-03-11 一种新circRNA、试剂盒及用途

Country Status (1)

Country Link
CN (1) CN114634932B (zh)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349464A1 (en) * 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding RNAS
CN109913459A (zh) * 2019-03-26 2019-06-21 首都医科大学附属北京友谊医院 一种新circRNA及其用途
CN110468130A (zh) * 2019-08-09 2019-11-19 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
CN110662421A (zh) * 2017-01-19 2020-01-07 开放式单克隆技术股份有限公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
CN111096973A (zh) * 2020-01-02 2020-05-05 滨州医学院 下调环状基因表达的试剂在制备预防和/或治疗肺纤维化的药物中的应用及药物
CN112243955A (zh) * 2020-10-23 2021-01-22 中国医学科学院北京协和医院 新型pls3基因敲除大鼠动物模型的构建方法和应用
CN112969367A (zh) * 2018-09-13 2021-06-15 瑞泽恩制药公司 作为c3肾小球病模型的补体因子h基因敲除大鼠
US11045546B1 (en) * 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN113755569A (zh) * 2021-08-27 2021-12-07 浙江百越生物技术有限公司 一种作为诊断急性肺损伤的标志物及其应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349464A1 (en) * 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding RNAS
CN110662421A (zh) * 2017-01-19 2020-01-07 开放式单克隆技术股份有限公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
CN112969367A (zh) * 2018-09-13 2021-06-15 瑞泽恩制药公司 作为c3肾小球病模型的补体因子h基因敲除大鼠
CN109913459A (zh) * 2019-03-26 2019-06-21 首都医科大学附属北京友谊医院 一种新circRNA及其用途
CN110468130A (zh) * 2019-08-09 2019-11-19 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
CN111096973A (zh) * 2020-01-02 2020-05-05 滨州医学院 下调环状基因表达的试剂在制备预防和/或治疗肺纤维化的药物中的应用及药物
WO2021136541A1 (zh) * 2020-01-02 2021-07-08 滨州医学院 下调环状基因表达的试剂在制备预防和/或治疗肺纤维化的药物中的应用及药物
US11045546B1 (en) * 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN112243955A (zh) * 2020-10-23 2021-01-22 中国医学科学院北京协和医院 新型pls3基因敲除大鼠动物模型的构建方法和应用
CN113755569A (zh) * 2021-08-27 2021-12-07 浙江百越生物技术有限公司 一种作为诊断急性肺损伤的标志物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张梦洁;缪红军;: "环状RNA在免疫应答及肺部感染性疾病中的作用", 医学综述, no. 07 *

Also Published As

Publication number Publication date
CN114634932B (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
Peng et al. Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1
CN109913545B (zh) 一种缺氧缺血性脑损伤诊断靶点及应用
CN108103206B (zh) 一种肌内脂肪相关的lncRNA及其应用
CN107881249B (zh) lncRNA及其靶基因在选育高品质畜禽品种中应用
EP2867376A1 (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
CN109913458B (zh) circRNA及其在检测缺氧缺血性脑损伤中的应用
CN111560435A (zh) 一种用于结直肠癌检测的dna甲基化试剂盒及使用方法、应用
Xu et al. Novel copy number variation of the KLF3 gene is associated with growth traits in beef cattle
WO2014114802A1 (en) Non-invasive prenatal genetic diagnostic methods
CN110964823A (zh) 用于结直肠癌检测的dna甲基化试剂盒和检测方法
CN110423811A (zh) 脓毒症诊断标志物
CN109913459B (zh) 一种新circRNA及其用途
Huang et al. MicroRNA sequence analysis of plasma exosomes in early Legg–Calvé–Perthes disease
CN108085399B (zh) lncRNA及其反式调控基因WNT11的新用途
CN105802969A (zh) lncRNA ENST00000581794.1及制剂或诊断剂或药物或试剂盒和应用
CN106086017A (zh) Enst00000509938.1及制剂或诊断剂或药物或试剂盒和应用
CN109022583A (zh) hsa_circ_0021977在制备诊断乳腺癌产品上的应用
CN114634932B (zh) 一种新circRNA、试剂盒及用途
CN110408692A (zh) 血液中的分子作为诊断脓毒症的标志物
CN113403383B (zh) 一种与先天性巨结肠发生相关的标志物及其应用
CN113025707A (zh) 生物标志物在制备诊断湿热困脾型2型糖尿病的产品中的应用、试剂盒
CN108103207B (zh) Brca1、jaml及其调控基因在品种选育中的应用
CN108103064B (zh) 长链非编码rna及其应用
CN106701761A (zh) 长链非编码rna nr‑027469.1及制剂或诊断剂或药物或试剂盒和应用
CN102757965B (zh) 血清microRNA分子标志物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Huang Yan

Inventor after: Li Feng

Inventor after: Zhang Anqi

Inventor after: Zhao Dahai

Inventor after: Li Yangyang

Inventor after: Wu Qiang

Inventor after: Tan Yuanyuan

Inventor after: Meng Xiaoming

Inventor after: Wang Yuanyuan

Inventor after: Jin Juan

Inventor after: Xu Zhenshan

Inventor before: Huang Yan

Inventor before: Li Feng

Inventor before: Zhang Anqi

Inventor before: Zhao Dahai

Inventor before: Li Yangyang

Inventor before: Wu Qiang

Inventor before: Tan Yuanyuan

Inventor before: Meng Xiaoming

Inventor before: Wang Yuanyuan

Inventor before: Jin Juan

Inventor before: Xu Zhenshan

GR01 Patent grant
GR01 Patent grant